MindMed Inc., Author at MicroSmallCap

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication NEW YORK, May 17, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(DE: BGHM)(OTCQB:MNMD) (“MindMed” or the “Company”), a leading clinical-stage psychedelic ... [Read]

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

Feb 11 MindMed Inc.

ZUG, Switzerland, Feb. 11, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(DE: BGHM)(OTCQB:MMEDF), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds ... [Read]